A Genome-Wide Association Meta-Analysis of Circulating Sex Hormone–Binding Globulin Reveals Multiple Loci Implicated in Sex Steroid Hormone Regulation

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Coviello, Andrea D., Robin Haring, Melissa Wellons, Dhananjay Vaidya, Terho Lehtimäki, Sarah Keildson, Kathryn L. Lunetta, et al. 2012. A genome-wide association meta-analysis of circulating sex hormone–binding globulin reveals multiple loci implicated in sex steroid hormone regulation. PLoS Genetics 8(7): e1002805.

Published Version
doi:10.1371/journal.pgen.1002805

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:10465991

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
A Genome-Wide Association Meta-Analysis of Circulating Sex Hormone–Binding Globulin Reveals Multiple Loci Implicated in Sex Steroid Hormone Regulation

Andrea D. Coviello1,2,3, Robin Haring4,5, Melissa Wellons6,7, Dhananjay Vaidya6,8, Terho Lehtimäki9,10, Sarah Keildson11,12, Chunya He13,14, Myriam Fornage12, Vasiliakos Lagou15,16, Massimo Mangino17,18, N. Charlotte Onland-Moret19, Brian Chen20, Joel Eriksson21, Melissa Garcia22, Yong Mei Liu23,24,25, Annemarie Koster21, Kurt Lohman26, Leo-Pekka Lyytikäinen7, Ann-Kristin Petersen22, Jennifer Prescott23,24, Lisette Stolk25,26, Liesbeth Vandenput27, Andrew R. Wood27, Wei Vivian Zhuang9, Aimo Ruokonen28, Anna-Liisa Hartikainen29, Anneli Pouta30, Stefania Bandinelli31, Reiner Biffar32, Georg Brabant33, David G. Cox34,35, Yuhui Chen8, Steven Cummings36, Luigi Ferruccioni37, Marc J. Gunter35, Susan E. Hankinson24,38,39, Hannu Martikainen29, Albert Hofman26,40, Georg Homuth41, Thomas Illig42,43, John-Olov Jansson17, Andrew D. Johnson3, David Karasik44, Magnus Karlsson45, Johannes Kettunen46,47, Douglas P. Kiel44, Peter Kraft48, Jingmin Liu9, Östen Ljunggren50, Mattias Lorentzon17, Marcello Maggio51, Marcello R. P. Markus52, Dan Mellström17, Iva Miljkovic53, Daniel Mirel54, Sarah Nelson55, Laure Morin Papunen29, Petra H. M. Peeters15, Inga Prokopenko8,13, Leslie Raffel56, Martin Reincke57, Alex P. Reiner58, Kathryn Rexrode59, Fernando Rivadeneira25,26, Stephen M. Schwartz20, David Siscovick50, Nicole Soranzo14,61, Doris Stöck62,63, Shelley Tooher24,39, André G. Uitterlinden25,26,40, Carla H. van Gils15, Ramachandran S. Vasan1,3, H.-Erich Wichmann64,65,66, Guangju Zhai14,67, Shalender Bhasin7, Martin Bidlingmaier57, Stephen J. Chanock68, Immaculata De Vivo23,24, Tamara B. Harris21, David J. Hunter23,24, Mika Kähönen69, Simin Liu70, Pamela Ouyang71, Tim D.pector14, Yvonne T. van der Schouw15, Jorma Viikari72, Heni Wallaschofski4, Mark I. McCarthy8,73,74, Timothy M. Frayling77, Anna Murray27, Steve Franks75, Marjo-Riitta Järvelin76,77,78,79, Frank H. de Jong25, Olli Raitakari80, Alexander Teumer41, Claes Ohlsson17, Joanne M. Murabito3,81, John R. B. Perry8,14,27,√

1 Section of Preventive Medicine and Epidemiology, Boston University School of Medicine, Boston, Massachusetts, United States of America, 2 Section of Endocrinology, Diabetes, and Nutrition, Boston University School of Medicine, Boston, Massachusetts, United States of America, 3 National Heart, Lung, and Blood Institute’s The Framingham Heart Study, Framingham, Massachusetts, United States of America, 4 Institute for Chemical and Laboratory Medicine, University of Minnesota, Minneapolis, Minnesota, United States of America, 5 Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, 6 Department of Medicine, Duke University, Durham, North Carolina, United States of America, 7 Department of Clinical and Metabolic Research, University of Oxford, Oxford, United Kingdom, 8 Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom, 9 Institute of Genetic Epidemiology, Helmholtz Zentrum München, Munich, Germany, 10 Department of Public Health, Indiana University School of Medicine, Indianapolis, Indiana, United States of America, 11 Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, Indiana, United States of America, 12 University of Texas Health Sciences Center at Houston, Houston, Texas, United States of America, 13 Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, United Kingdom, 14 Department of Twin Research and Genetic Epidemiology, King’s College London, London, United Kingdom, 15 Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands, 16 Program on Genomics and Nutrition and the Center for Metabolic Disease Prevention, School of Public Health, University of California Los Angeles, Los Angeles, California, United States of America, 17 Center for Bone and Arthritis Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 18 Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, Maryland, United States of America, 19 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America, 20 Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States of America, 21 Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, Maryland, United States of America, 22 Institute of Genetic Epidemiology, Helmholtz Zentrum München, Munich, Germany, 23 Program in Molecular and Genetic Epidemiology, Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America, 24 Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Massachusetts, United States of America, 25 Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands, 26 Netherlands Consortium of Healthy Aging, Rotterdam, The Netherlands, 27 Genetics of Complex Traits, Peninsula Medical School, University of Exeter, Exeter, United Kingdom, 28 Institute of Diagnostics, University of Oulu, Oulu, Finland, 29 Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland, 30 National Institute for Health and Welfare and Institute of Health Sciences, University of Oulu, Oulu, Finland, 31 Geriatric Unit, Azienda Sanitaria di Firenze, Florence, Italy, 32 Department of Prosthetic Dentistry, Gerostomatology, and Dental Materials, University of Greifswald, Greifswald, Germany, 33 Experimental and Clinical Endocrinology, University of Lübeck, Lübeck, Germany, 34 Cancer Research Center of Lyon, INSERM U1052, Lyon, France, 35 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom, 36 California Pacific Medical Center, San Francisco, California, United States of America, 37 Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Baltimore, Maryland, United States of America, 38 Division of Biostatistics and Epidemiology, University of Massachusetts, Amherst, Massachusetts, United States of America, 39 Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America, 40 Department of Epidemiology, Erasmus MC, Rotterdam, The Netherlands, 41 Interfaculty Institute for Genetics and Functional Genomics, University of Greifswald, Greifswald, Germany, 42 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, Neuhberg, Germany, 43 Hannover Unified Biobank, Hannover Medical School, Hannover, Germany, 44 Hebrew SeniorLife Institute for Aging Research and Harvard Medical School, Boston, Massachusetts, United States of America, 45 Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences and Department of Orthopaedics, Lund University, Malmö, Sweden, 46 Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland, 47 Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki,
Sex hormone-binding globulin (SHBG) is a glycoprotein responsible for the transport and biologic availability of sex steroid hormones, primarily testosterone and estradiol. SHBG has been associated with chronic diseases including type 2 diabetes (T2D) and with hormone-sensitive cancers such as breast and prostate cancer. We performed a genome-wide association study (GWAS) meta-analysis of 21,791 individuals from 10 epidemiologic studies and validated these findings in 7,046 individuals in an additional six studies. We identified twelve genomic regions (SNPs) associated with circulating SHBG concentrations. Loci near the identified SNPs included SHBG (rs12150660, 17p13.1, p = 1.8 x 10^{-14}), PRMT6 (rs17496332, 1p13.3, p = 1.4 x 10^{-16}), GCKR (rs780093, 2p23.3, p = 2.2 x 10^{-14}), ZBTB10 (rs440837, 8q21.13, p = 3.4 x 10^{-14}), MJD1C (rs7910927, 10q21.3, p = 6.1 x 10^{-18}), SLC19A1 (rs4149056, 12p12.1, p = 1.9 x 10^{-9}), NR2F2 (rs8023530, 15q26.2, p = 8.3 x 10^{-12}), ZNF652 (rs2411984, 17q21.32, p = 3.5 x 10^{-14}), TGDF3 (rs1573036, Xq22.3, p = 4.1 x 10^{-14}), LHCBG (rs10454142, 2p16.3, p = 1.3 x 10^{-10}), BAIAP2L1 (rs3779195, 7q21.3, p = 2.7 x 10^{-8}), and UGT2B15 (rs293428, 4q13.2, p = 5.5 x 10^{-8}). These genes encompass multiple biologic pathways, including hepatic function, lipid metabolism, carbohydrate metabolism and T2D, androgen and estrogen receptor function, epigenetic effects, and the biology of sex steroid hormone-responsive cancers including breast and prostate cancer. We found evidence of sex-differentiated genetic influences on SHBG. In a sex-specific GWAS, the loci 4q13.2-UGT2B15 was significant in men only (men p = 2.5 x 10^{-16}, women p = 0.66, heterogeneity p = 0.003). Additionally, three loci showed strong sex-differentiated effects: 17p13.1-SHBG and Xq22.3-TGDF3 were stronger in men, whereas 8q21.12-ZBTB10 was stronger in women. Conditional analyses identified additional signals at the SHBG gene that together almost double the proportion of variance explained at the locus. Using an independent study of 1,129 individuals, all SNPs identified in the overall or sex-differentiated or conditional analyses explained ~15.6% and ~8.4% of the genetic variation of SHBG concentrations in men and women, respectively. The evidence for sex-differentiated effects and allelic heterogeneity highlight the importance of considering these features when estimating complex trait variance.

Citation: Covillo AD, Haring R, Wellons M, Vaidya D, Lehtimäki T, et al. (2012) A Genome-Wide Association Meta-Analysis of Circulating Sex Hormone-Binding Globulin Reveals Multiple Loci Implicated in Sex Steroid Hormone Regulation. PLoS Genet 8(7): e1002805. doi:10.1371/journal.pgen.1002805

Editor: Greg Gibson, Georgia Institute of Technology, United States of America

Received February 20, 2012; Accepted May 19, 2012; Published July 19, 2012

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This meta-analysis is a collaborative effort involving data from many individual studies and many sources of funding. The details of funding sources for each study are detailed in Text S1 as well as below. Framingham Heart Study (PHS): The phenotype-genotype association analyses were funded through grants from the NIA R21 AG032598 (JM Murabito, KL Lunetta), R01 HL094755 (AD Covillo, RS Vasan, S Bandinelli), and R01 AG13206 (RS Vasan, S Bandinelli), R01 AR/AG 41398 (DP Kiel). This research was conducted in part using data and resources from the Framingham Heart Study of the National Heart, Lung, and Blood Institute of the National Institutes of Health and Boston University School of Medicine. The analyses reflect intellectual input and resource development from the Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARE) project. This work was partially supported by the National Heart, Lung, and Blood Institute’s Framingham Heart Study (Contract No. N01-HC-25195) and its contract with Affymetrix for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinCA-I), funded by the Robert Dawson Watson Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Gothenburg Osteoporosis and Obesity Determinants (GOOD) Study: Financial support was also received from the Swedish Research Council (K02010-54X-09894-193, 2006-3832, and K02010-54X-20229-05-3), the Swedish Foundation for Strategic Research, the ALF/LUA research grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg’s Foundation, Petrus and Augusta Hedlunds Foundation, the Vastra Götalnds Foundation, the Göteborg Medical Society, the Novo Nordisk foundation, and the European Commission grant HEALTH-F2-2008-201865-GEFOS. We would like to acknowledge Maria Nethander at the genomics core facility at University of Gothenburg for statistical analyses. We would also like to thank Dr. Tobias A. Knoch, Luc V. de Zeeuw, Anis Abuseiris, and Rob de Graaf as well as their institutions the Erasmus Computing Grid, Rotterdam, The Netherlands, and especially the national German MediGRID and Services@MediGRID part of the German D-Grid, both funded by the German Bundesministerium fuer Forschung und Technologie under grants #01 AK 803 A-H and #01 IG 07015 G for access to their grid resources. We would also like to thank Karol Estrada, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands, for advice regarding...
These authors also contributed equally to this work.

* E-mail: John.perry@pms.ac.uk (JRB Perry); murabito@bu.edu (JM Murabito)

Competing Interests: The authors declare that they have no competing interests.

* These authors contributed equally to this work.

† These authors contributed equally to this work.
Author Summary

Sex hormone-binding globulin (SHBG) is the key protein responsible for binding and transporting the sex steroid hormones, testosterone and estradiol, in the circulatory system. SHBG regulates their bioavailability and therefore their effects in the body. SHBG has been linked to chronic diseases including type 2 diabetes and to hormone-sensitive cancers such as breast and prostate cancer. SHBG concentrations are approximately 50% heritable in family studies, suggesting SHBG concentrations are under significant genetic control; yet, little is known about the specific genes that influence SHBG. We conducted a large study of the association of SHBG concentrations with markers in the human genome in ~22,000 white men and women to determine which loci influence SHBG concentrations. Genes near the identified genomic markers in addition to the SHBG protein coding gene included PRMT6, GCKR, ZBTB10, JMJD1C, SLCO1B1, NR2F2, ZNF652, TGF3, LHCGR, BAUDP2L1, and UGT2B15. These genes represent a wide range of biologic pathways that may relate to SHBG function and sex steroid hormone biology, including liver function, lipid metabolism, carbohydrate metabolism and type 2 diabetes, and the development and progression of sex steroid hormone-responsive cancers.

Introduction

Sex hormone-binding globulin (SHBG) is a protein secreted mainly by the liver that binds to the sex steroids, testosterone, dihydrotestosterone, and estradiol, transports them in the circulation, and influences their action in target tissues by regulating their bioavailability. SHBG thereby influences the expression of sex hormone sensitive phenotypes including sexual characteristics and reproductive function in men and women [1]. In addition to regulating sex steroid hormone effects, SHBG may exert independent effects through its own receptor [2]. Variation in SHBG concentration has also been associated with various chronic diseases including cancers [3], polycystic ovary syndrome (PCOS) [4,5] and type 2 diabetes (T2D) [6,7]. Although SHBG is estimated to have a heritable component (~50%) [8], little is known about the genetic regulation of SHBG. Polymorphisms at the SHBG gene locus have been associated with SHBG concentrations [9,10], but much remains unknown about specific genetic variants that may determine circulating SHBG concentrations. Identifying genetic factors that influence SHBG may provide insights into the biology of sex steroid hormone regulation, metabolism and tissue effects that underlie their relationship with chronic diseases such as T2D as well as hormone-sensitive cancers such as breast and prostate cancer.

Results

We identified nine loci associated with SHBG concentrations at the genome-wide significance threshold of \( p = 5 \times 10^{-8} \) (Table 1 and Figure 1) in a genome-wide association study (GWAS) meta-analysis of circulating SHBG concentrations in 21,791 men and women from 10 studies (Table S1). All nine lead SNPs at these loci had effects in the same direction (seven with \( p < 0.05 \)) in the validation dataset of 7,046 men and women from six additional studies (Table S2). The strongest association was within the SHBG locus (rs12150666, \( p = 2 \times 10^{-108} \)). Together, these nine lead SNPs explained 7.2% of the genetic variance (assuming 50% heritability) in SHBG concentrations.

We next performed a series of additional analyses to explain more of the phenotypic variance (Figure 2). First, we hypothesized that genetic effects may be different in men and women, as SHBG concentrations are >50% higher in females than males, and may be differentially regulated between sexes. In a sex stratified analysis, three of the nine loci showed evidence of sex-differentiated effects at \( p < 0.02 \) when we would not expect any signals to have reached this level of significance by chance. The associations at the 17p13.1-SHBG and Xq22.3 loci were stronger in males whereas the association at the 8q21.3 locus was stronger in females. To investigate the apparent differential sex effect for the X chromosome further we ran a recessive regression model for the X chromosome SNP rs1573036 in women in the Framingham Heart Study and found no association with SHBG suggesting the sex-differentiated effect is not the result of a recessive inheritance pattern. Sex stratified GWAS identified one novel signal in men, which showed no association in women (4q13.2: men \( p = 2.5 \times 10^{-6} \), women \( p = 0.66 \), heterogeneity \( p = 0.003 \)).

A series of conditional analyses were performed to identify statistically independent signals. At the SHBG locus, three apparently independent additional signals separate from the main index SNP were observed, based on low \( r^2<0.05 \) pairwise correlations in HapMap (rs6258 p = 2.7 \times 10^{-46}, rs1625895 p = 1.2 \times 10^{-14} and rs3833894 p = 2.5 \times 10^{-11}). A series of iterative conditional analyses (Table 2) involving SNPs at the SHBG locus generated a final regression model including six statistically independent SHBG SNPs. Four of these SNPs (#1–4 Table 2) retained GWS when conditioned against the other five, and two were nominally associated (SNP #5 p = 0.0001, SNP #6 p = 0.01). Re-running the GWAS meta-analysis adjusting for these six SNPs revealed evidence for three additional statistically independent (pairwise HapMap \( r^2<0.01 \)) signals at the SHBG locus (SNP #7 p = 1.5 \times 10^{-5}, SNP #8 p = 4.6 \times 10^{-3}, SNP #9 p = 9.9 \times 10^{-6}) (Figure 3). There were also two additional trans signals located at 2p16.3 and 7q21.3 (Table 1). Although the 2p16.3 signal dropped below GWS when combined with follow-up samples (\( p = 1 \times 10^{-7} \)), the index SNP at 2p16.3 is ~300 kb away from a strong candidate gene, the luteinizing hormone receptor gene (LHCGR).

The majority of pair-wise correlations for the nine SHBG locus SNPs highlighted by our conditional analyses showed very low HapMap \( r^2 \) values. However, the pairwise D’ values are often high (Table S3) indicating that no or few recombination events have occurred between some SNPs, and that combinations of SNPs may be tagging un-typed variants on a common haplotype. To investigate this possibility, we performed more extensive analyses in a single study (NFBC1966, \( n = 4467 \)) in the June 2011 version of the 1000 Genomes data and performed model selection analyses. Model selection identifies a set of SNPs that best explain phenotypic variation, while simultaneously penalizing each SNP included in this set, and therefore correlated SNPs tend to be excluded from the final model. These analyses consistently included at least seven SNPs in the model, although it is hard to estimate the false-negative rate of using the reduced sample size. While we are underpowered to accurately pinpoint the exact number of independent signals, these analyses support the results of the conditional analysis and suggest that multiple variants at the SHBG locus are independently associated with SHBG concentrations.

Data from an independent study, the InCHIANTI study, was used to calculate the proportion of genetic variance in SHBG concentrations explained when accounting for sex specific effects, the multiple signals of association at the SHBG locus, and the additional trans signals identified post conditional analysis. In men and women we explained ~15.6% and ~8.4% of the heritable
Table 1. SNPs representing loci associated with circulating SHBG concentrations.

| Index SNP | Analysis | Region | Nr Gene | Chr | Position | Effect Allele | Other Allele | EAF | Beta | SE | p    | Beta | SE | p | Sex |
|-----------|----------|--------|---------|-----|----------|---------------|--------------|-----|------|----|-----|------|----|----|-----|
| rs17496332 | Main | 1p13.3 | PRMT6 | 1   | 107347898 | a              | g            | 0.67 | -0.026 | 0.0046 | 1.0E-08 | -0.028 | 0.0041 | 1.4E-11 | Females |
| rs780093   | Main | 2p23.3 | GCKR  | 2   | 27596107  | t              | c            | 0.40 | -0.033 | 0.0043 | 5.8E-14 | -0.032 | 0.0039 | 2.2E-16 | Females |
| rs440837   | Main | 8q21.13 | ZBTB10 | 8   | 81624529  | a              | g            | 0.78 | -0.030 | 0.0052 | 6.7E-09 | -0.028 | 0.0047 | 3.4E-09 | Females |
| rs7910927  | Main | 10q21.3 | JMJD1C | 10  | 64808916  | t              | g            | 0.51 | -0.044 | 0.0043 | 7.4E-25 | -0.048 | 0.0039 | 6.1E-35 | Females |
| rs4149056  | Main | 12p12.1 | SLCO1B1 | 12  | 21222816  | t              | c            | 0.82 | 0.032  | 0.0057 | 1.5E-08 | 0.029  | 0.0052 | 1.9E-08 | Females |
| rs8023580  | Main | 15q26.2 | NR2F2  | 15  | 94509295  | t              | c            | 0.72 | -0.029 | 0.0049 | 2.8E-09 | -0.03  | 0.0044 | 8.3E-12 | Females |
| rs12150660 | Main | 17p13.1 | SHBG  | 17  | 7462640   | t              | g            | 0.24 | 0.100  | 0.0053 | 1.2E-07 | 0.103  | 0.0047 | 1.8E-10 | Females |
| rs2411984  | Main | 2q13.2 | ZNF652 | 17  | 4880750   | a              | g            | 0.28 | 0.034  | 0.0049 | 1.5E-12 | 0.033  | 0.0044 | 3.5E-14 | Females |
| rs440837   | Main | 17p13.1 | SHBG  | 17  | 7462640   | t              | g            | 0.24 | 0.100  | 0.0053 | 1.2E-07 | 0.103  | 0.0047 | 1.8E-10 | Females |
| rs780093   | Main | 2p23.3 | GCKR  | 2   | 27596107  | t              | c            | 0.40 | -0.033 | 0.0043 | 5.8E-14 | -0.032 | 0.0039 | 2.2E-16 | Females |
| rs440837   | Main | 8q21.13 | ZBTB10 | 8   | 81624529  | a              | g            | 0.78 | -0.030 | 0.0052 | 6.7E-09 | -0.028 | 0.0047 | 3.4E-09 | Females |
| rs7910927  | Main | 10q21.3 | JMJD1C | 10  | 64808916  | t              | g            | 0.51 | -0.044 | 0.0043 | 7.4E-25 | -0.048 | 0.0039 | 6.1E-35 | Females |
| rs4149056  | Main | 12p12.1 | SLCO1B1 | 12  | 21222816  | t              | c            | 0.82 | 0.032  | 0.0057 | 1.5E-08 | 0.029  | 0.0052 | 1.9E-08 | Females |
| rs8023580  | Main | 15q26.2 | NR2F2  | 15  | 94509295  | t              | c            | 0.72 | -0.029 | 0.0049 | 2.8E-09 | -0.03  | 0.0044 | 8.3E-12 | Females |
| rs12150660 | Main | 17p13.1 | SHBG  | 17  | 7462640   | t              | g            | 0.24 | 0.100  | 0.0053 | 1.2E-07 | 0.103  | 0.0047 | 1.8E-10 | Females |
| rs2411984  | Main | 2q13.2 | ZNF652 | 17  | 4880750   | a              | g            | 0.28 | 0.034  | 0.0049 | 1.5E-12 | 0.033  | 0.0044 | 3.5E-14 | Females |
| rs440837   | Main | 8q21.13 | ZBTB10 | 8   | 81624529  | a              | g            | 0.78 | -0.030 | 0.0052 | 6.7E-09 | -0.028 | 0.0047 | 3.4E-09 | Females |
| rs7910927  | Main | 10q21.3 | JMJD1C | 10  | 64808916  | t              | g            | 0.51 | -0.044 | 0.0043 | 7.4E-25 | -0.048 | 0.0039 | 6.1E-35 | Females |
| rs4149056  | Main | 12p12.1 | SLCO1B1 | 12  | 21222816  | t              | c            | 0.82 | 0.032  | 0.0057 | 1.5E-08 | 0.029  | 0.0052 | 1.9E-08 | Females |
| rs8023580  | Main | 15q26.2 | NR2F2  | 15  | 94509295  | t              | c            | 0.72 | -0.029 | 0.0049 | 2.8E-09 | -0.03  | 0.0044 | 8.3E-12 | Females |
| rs12150660 | Main | 17p13.1 | SHBG  | 17  | 7462640   | t              | g            | 0.24 | 0.100  | 0.0053 | 1.2E-07 | 0.103  | 0.0047 | 1.8E-10 | Females |

All SNPs are on the + strand and positions are based on build 36. EAF = 'effect allele frequency'. Beta units are per-allele effect estimates in natural log transformed nmol/L. Sex column gives the sex with the largest per-allele beta estimate. Missing values for conditional SNPs as sex-specific conditional analysis was not performed.
component respectively. The \textit{SHBG} locus accounted for \(\sim 10\%\) and \(\sim 6.6\%\) of the genetic variation in men and women respectively with the lead SNP in isolation accounting for \(\sim 7.8\%\) and \(\sim 3.3\%\) of the variation in men and women, respectively.

We identified genes near the associated SNPs and explored their biologic relevance to \textit{SHBG}. The genes associated with identified SNPs included the \textit{SHBG} locus (rs12150660, 17p13.1, \(p = 1.8 \times 10^{-10}\)), \textit{PRMT6} (rs17496332, 1p13.3, \(p = 1.4 \times 10^{-11}\)), \textit{GCKR} (rs780093, 2p23.3, \(p = 2.2 \times 10^{-16}\)), \textit{ZBTB10} (rs40837, 8q21.13, \(p = 3.4 \times 10^{-9}\)), \textit{JMJD1C} (rs7910927, 10q21.3, \(p = 6.1 \times 10^{-35}\)), \textit{SLCO1B1} (rs4149056, 12p12.1, \(p = 1.9 \times 10^{-48}\)), \textit{NR2F2} (rs8023580, 15q26.2, \(p = 8.3 \times 10^{-12}\)), \textit{ZNF652} (rs2411984, 17q21.32, \(p = 3.5 \times 10^{-14}\)), \textit{TDGF3} (rs1573036, Xq22.3, \(p = 4.1 \times 10^{-8}\)), \textit{LHCGR} (rs10454142, 2p16.3, \(p = 1.5 \times 10^{-10}\)), \textit{BAIAP2L1} (rs3779195, 7q21.3, \(p = 2.7 \times 10^{-9}\)), and \textit{UGT2B15} (rs293428, 4q13.2, \(p = 5.5 \times 10^{-10}\)) (Figure 1).

We used the online tool STRING (www.string-db.org) to perform pathway analyses to explore possible interactions between the \textit{SHBG} gene and the proteins encoded by the 11 most plausible genes near the 11 SNPs listed above. There was an interaction noted between \textit{GCKR} and \textit{JMJD1C} which were associated with the lipoprotein fractions VLDL and HDL, respectively [11]. In an expanded analysis, we assessed protein interactions among \textit{SHBG} and 67 genes within 500 kb of our 11 identified SNPs and uncovered additional protein interaction pathways. An interaction between two proteins encoded by \textit{GTF2A1} and \textit{STON1} was found; these proteins are co-expressed in testicular germ cells in the mouse [12]. An interaction between \textit{LHCGR} and \textit{BR3} encoded proteins that are associated with the G-protein coupled receptor complex in the human luteinizing hormone receptor was also identified [13]. Finally, an interaction between \textit{LHCGR} and \textit{LAPP} (amylin) proteins which are components of a ligand/G-protein receptor/G-protein alpha subunit complex was found (database: www.reactome.com).

Targeted analysis of two strong candidate genes, hepatocyte nuclear factor-4\(\alpha\) (\textit{HNF4\(\alpha\)}) and peroxisome-proliferating receptor \(\gamma\) (\textit{PPAR\(\gamma\)}) did not identify any SNPs at \textit{HNF4\(\alpha\)} but did identify one SNP, rs2920502, at \textit{PPAR\(\gamma\)} that reached statistical significance (\(p = 9.9 \times 10^{-7}\)) and a second SNP at \textit{PPAR\(\gamma\)}, rs13081389, that reached nominal significance (\(p = 0.01\)).

Discussion

In total, we identified 12 genomic regions associated with circulating \textit{SHBG} concentrations, including extensive allelic heterogeneity at the \textit{SHBG} locus itself. Conditional meta-analyses carried out at the \textit{SHBG} locus, identified nine genome-wide significant SNPs with low correlation (\(r^2 < 0.01\)) between them. Two of these signals (rs6258 [10] and rs6259) are missense variants and two are low frequency variants (MAF < 2\%). Furthermore, rs12150660 is highly correlated (\(r^2 > 0.95\)) [10] with a pentanu-
A CTCG repeat, which affects SHBG expression in-vitro [14]. To our knowledge, the magnitude of secondary signals observed at this locus are the largest seen for any complex trait.

The proportion of genetic variance in SHBG serum concentrations explained when accounting for sex specific effects, the multiple signals of association at the SHBG locus, and the

Table 2. Statistically independent signals at the SHBG gene locus.

| SNP # | Model        | Conditioned On SNP # | SNP      | Position | Effect Allele | Other Allele | EAF  | Beta     | SE     | p-value       | Discovery p-value | Discovery Beta |
|-------|--------------|----------------------|----------|----------|---------------|--------------|------|----------|--------|---------------|-----------------|----------------|
| 1     | Full model   | 2–6                  | rs12150660 | 7462640  | t             | g            | 0.24 | 0.082    | 0.005  | 1.89E-55      | 1.19E-79        | 0.10           |
| 2     | Full model   | 1,3–6                | rs6258   | 7475403  | t             | c            | 0.02 | -0.272   | 0.017  | 1.03E-60      | 2.69E-46        | 0.2613         |
| 3     | Full model   | 1–2,4–6              | rs1641537| 7486446  | t             | c            | 0.14 | -0.064   | 0.006  | 1.20E-24      | 8.19E-39        | 0.0814         |
| 4     | Full model   | 1–3,5–6              | rs1625895| 7518840  | t             | c            | 0.12 | -0.06    | 0.006  | 1.75E-21      | 1.17E-14        | 0.052          |
| 5     | Full model   | 1–4,6                | rs6259   | 7477252  | a             | g            | 0.11 | 0.026    | 0.007  | 0.0001        | 1.46E-07        | 0.0372         |
| 6     | Full model   | 1–5                  | rs10432029| 7331393  | a             | g            | 0.79 | 0.0136   | 0.006  | 7.52E-16      | 0.0446          |                |
| 7     | Conditional  | 1–6                  | rs9901675| 7425536  | a             | g            | 0.05 | -0.057   | 0.01   | 1.46E-07      | 5.2E-12         | -0.07          |
| 8     | Conditional  | 1–6                  | rs8077824| 7588951  | a             | g            | 0.02 | 0.075    | 0.018  | 4.58E-05      | 0.01            | 0.0451         |
| 9     | Conditional  | 1–6                  | rs9303218| 7339386  | t             | c            | 0.77 | 0.026    | 0.006  | 9.89E-06      | 1.21E-11        | 0.0344         |

All SNPs are on the + strand and positions are based on build 36. EAF = ‘effect allele frequency’. Beta units are per-allele effect estimates in natural log transformed nmol/L. ‘Full model’ SNPs were all included in a single regression model, where the effect estimates for each SNP are adjusted for the effect of the others in the model. ‘Conditional’ SNPs are SNPs with low pair-wise LD (HapMap r²<0.01) that were identified after conditioning on the full model SNPs.

doi:10.1371/journal.pgen.1002805.t002
additional \( t \)ran signals identified post conditional analysis was \( \sim 15.6\% \) in men and \( \sim 8.4\% \) in women. The \( SHBG \) locus accounted for \( \sim 10\% \) and \( \sim 6.6\% \) of the genetic variance in men and women, respectively, with the lead SNP explaining most of the genetic variation at \( \sim 7.8\% \) for men and \( \sim 3.3\% \) for women. Thus additional signals at the \( SHBG \) locus identified through conditional analyses approximately doubled the variance of the trait explained. While we provide evidence for multiple variants associated with \( SHBG \) concentrations, further studies are needed to pinpoint the causal loci and functional variants. For the 11 regions outside the \( SHBG \) locus, most have biologically plausible related genes within 300 kb.

**Biology of Plausible Genes near Identified SNPs**

Several genes near the identified SNPs regulate sex steroid production and function. The \( NR2F2 \) locus (15q26.2) encodes a nuclear receptor important in testicular Leydig cell function, the primary source of gonadal testosterone production [15], and has been linked to male infertility [16]. \( NR2F2 \) has also been associated with estrogen receptor alpha (ER\( \alpha \)) signaling and may influence hormone responsivity in breast cancer [17]. \( PRMT6 \) (1p13.3) also encodes a nuclear receptor regulatory protein that mediates estrogen signaling as a co-activator of the estrogen receptor [18]. \( LHCGR \) (2p16.3) encodes the luteinizing hormone receptor which was associated with polycystic ovary syndrome (PCOS) in a recent GWAS [19,20]. PCOS is both a reproductive and metabolic disorder characterized by higher testosterone serum concentrations as well as an increased prevalence of obesity, insulin resistance, and T2D in women. Inappropriate secretion of luteinizing hormone leads to increased ovarian production of testosterone. Coincident lower \( SHBG \) concentrations contribute to increased bioavailable testosterone concentrations and the expression of both reproductive and metabolic phenotypes in PCOS [21,22,23].

The \( SLC01B1 \) locus encodes a liver-specific transporter of thyroid hormone as well as estrogens which impact liver production of \( SHBG \) [24]. \( JMJD1C \) (10q21.3), also known as \( TRIP \beta \) (thyroid hormone receptor interactor protein 8 [25]), may impact \( SHBG \) concentrations via thyroid hormone effects on liver protein production. Thyroid hormone may alter \( SHBG \) production through effects on \( INF \) which is known to regulate \( SHBG \) transcription [26,27].

Many of the genes identified are involved in carbohydrate and lipid metabolism and liver function. The \( GCKR \) locus (2p23.3) encodes a protein that regulates glucokinase activity and has been associated with T2D in several ethnic populations [28,29,30,31]. \( GCKR \) has been associated with metabolic and inflammatory traits including triglyceride concentrations and other lipid fractions [30,32], fasting plasma glucose [33,34], insulin concentrations, uric acid, c-reactive protein (CRP), and non-alcoholic fatty liver disease which are all characteristic of the metabolic syndrome and T2D [28,35,36,37,38,39,40,41,42]. The \( SLC01B1 \) locus (12p12.1) also encodes a protein, hepatocyte protein anion-transporting polypeptide 1B1, involved in liver metabolism of both endogenous and exogenous compounds [43]. Consistent with \( SLC01B1 \)’s role in liver metabolism, the same SNP (rs4149056) has been associated with circulating bilirubin concentrations in previous GWAS [44]. \( BAIAP2L1 \) (7q21.3) encodes a protein important in cytoskeleton organization [45] that has been associated with the inflammatory marker CRP in patients with arthritis [46]. \( BAIAP2L1 \) is also known as \( IRTKS \) (insulin receptor tyrosine kinase substrate) which

![Figure 3. Allelic heterogeneity at the \( SHBG \) gene locus. There was significant allelic heterogeneity at the \( SHBG \) gene locus. The nine independent signals identified in the \( SHBG \) gene are shown in relation to their position within the gene. All positions based on build 36. Not all genes are shown. doi:10.1371/journal.pgen.1002805.g003](image-url)
is involved in insulin receptor signaling [47] and may relate to insulin resistant states including obesity and T2D [40,49, 50,51,52,53,54]. We conducted a targeted analysis of PPARγ, a gene that influences SHBG gene expression in the liver [1,55] and is associated with T2D [56,57]. Our analysis identified one significant SNP (rs2920502, \(p = 9.9 \times 10^{-5}\)) and a second nominally significant SNP (rs13081389, \(p = 0.01\)) at PPARγ. Some of the identified genes involved in hepatic metabolism of lipids and carbohydrates may be affect SHBG concentrations indirectly through effects on the SHBG transcription regulator HNF4α although HNF4α itself was not identified in this meta-analyses [27,58,59,60].

The UGT2B15 locus (4q13.2) was significantly associated with SHBG concentrations in men but not women in this meta-analysis. UGT2B15 belongs to a family of genes (the UGT2B gene family) that code for enzymes involved in the metabolism of sex hormones through glucuronidation which allows for excretion of sex steroids through the kidney and the gut via bile excretion [61,62], primary clearance mechanisms for sex steroids [63]. UGT2B15 is involved in the conjugation and inactivation of testosterone [64]. An association between rs293428 in the UGT2B15 locus and circulating SHBG concentrations in men is supported by a previous study demonstrating that a non-synonymous SNP in UGT2B15 (r19902023; D85Y) is associated with serum SHBG concentrations in younger adult men [65]. UGT2B15 is thought to play a significant role in local tissue inactivation of androgens in androgen dependent prostate cancer [66,67]. The mechanism behind the influence of genetic variants in UGT2B15 on SHBG concentrations is unknown, but one may speculate that UGT2B15 affects the local androgenic environment in selected tissues, which in turn results in regulation of SHBG concentrations.

In addition to UGT2B15, three other genes near the identified SNPs are associated with carcinogenesis, particularly in the prostate and breast. ZBTB10 (8q21.13), has been linked to breast cancer [68]. In breast cancer cell lines ZBTB10 is suppressed by ROS-microRNA27α thereby enhancing ERα expression and mediating estrogen effects [17]. The ZNF652 (17q21.32) locus codes for a DNA binding protein thought to act as a tumor suppressor gene in breast cancer [69,70,71] that is also co-expressed with the androgen receptor in prostate cancer [72]. TDGF3, teratocarcinoma derived growth factor 3, is the only significant region identified on the X chromosome (Xq22.3). TDGF3 is a pseudogene of TDGF1 located on chromosome 3p23-p21 that has been associated with testicular germ cell tumors [73].

Strengths and Limitations

This GWAS meta-analysis incorporated data from approximately 22,000 men and women from 16 epidemiologic cohorts. The overall size of the study yields power but the meta-analysis of data from different epidemiologic studies requires the inclusion of different laboratory methods. The different studies used a variety of assay methodologies to measure serum SHBG concentrations although the vast majority were immunoassays (Tables S1 and S2, Text S1) with similar methodologies. Variation introduced by the use of different SHBG assays would result in loss of statistical power and likely bias toward the null. Additionally, the majority of women were post-menopausal as ascertained by self-report in all studies (Table S1). SHBG concentrations, like testosterone, decline only slightly across the menopause [74] so adjustment for menopause status is not necessary. SHBG may also increase with ovulation and be slightly higher in the luteal versus the follicular phase of the menstrual cycle in premenopausal women, but most studies did not collect data on menstrual phase at the time of

SHBG measurement so adjustment for menstrual phase was not possible [75]. Finally, individuals were not excluded based on health status, therefore some individuals with chronic conditions that may affect hepatic production of or clearance of proteins including SHBG such as liver disease, renal disease, or severe malnutrition, may have been included in this analysis.

Conclusion

SHBG synthesis in the liver is known to be affected directly or indirectly by estrogens, androgens and thyroid hormones and has been observed to be inversely associated with the higher insulin concentrations characteristic of insulin resistant states such as T2D [1,6]. In summary, the results of this GWAS reflect these influences. Three regions map to proteins related to hepatic function [12p12.1-SLC01B1 [76], 2p23.3-GCKR [77] and 10q21.3-3MJDIC [77]]. In addition, 2p23.3-GCKR and 7q21.3-BMAL2P1 [alias insulin receptor tyrosine kinase substrate (IRTKS)] are involved in susceptibility to T2D [48] and insulin signaling [47], respectively. Two signals also mapped to loci involved in thyroid hormone regulation [10q21.3-JMJDIC and 12p12.1-SLC01B1]. One signal mapped to the receptor for luteinizing hormone 2p16.3-LHGR [29], the hormone that stimulates testosterone production. Five regions mapped to genes previously implicated in androgen and estrogen signaling [1p13.3-PRMT6 [18], 8q21.3-ZBTB10 [17], 12p12.1-SLC01B1 [76], 15q26.2-NR2F2 [78], 4q13.2-UGT2B15 [63]].

We have combined a conventional GWAS approach with detailed additional analyses, including sex stratification, conditional analysis and imputation from 1000 Genomes. Our results demonstrate that these approaches can lead to an appreciable gain in heritable variance explained. It does however highlight the complexity of elucidating individual variant causality through statistical approaches. In addition to the extensive allelic heterogeneity at the SHBG locus, our data identify loci with a role in sex steroid hormone metabolism, which may help elucidate the role of sex steroid hormones in disease, particularly T2D and hormone-sensitive cancers.

Methods

We performed a genome wide association study (GWAS) meta-analysis of 21,791 individuals (Table S1: 9,390 women, 12,401 men) from ten observational studies. Data from an additional six studies totaling 7,046 individuals (Table S2: 4,509 women; 2,537 men) were used for validation. The proportion of variance explained was estimated in an independent study (InCHIANTI, \(n = 1,129\)). The individual study protocols were approved by their respective institution’s ethics committee/institutional review board and all participants provided informed consent prior to participation. Individuals known to be taking hormonal contraceptives or hormone replacement therapy at time of SHBG measurement were excluded from analysis. Age, sex and body mass index (BMI) were included as covariates. After applying standard quality control measures, imputed genotypes were available for approximately 2.5 M SNPs. See Figure 2 for an overview of the analytic plan and the Text S1 for further information for individual studies included in this meta-analysis.

GWAS Conditional Meta-Analysis Steps

**Conditional analysis #1.** The initial starting point for the conditional analysis was the four SHBG locus SNPs that all showed low Hapmap LD (\(r^2<0.05\)) with each other: rs12150660 (lead SNP Table 1), rs6258 p = 2.7 × 10^{-10}; rs1625895 p = 1.2 × 10^{-14} and rs3653894 p = 2.3 × 10^{-31}. Each cohort fitted a single
regression model, fitting SHBG concentrations against these four genome-wide significant SHBG locus SNPs (rs12150660, rs6258, rs1625895 and rs3853894), in addition to age, sex and BMI. After meta-analyzing the results from all cohorts, three of the SNPs retained genome-wide significance when regressed against each other, with the fourth SNP narrowly missing that threshold (rs3853894, \( p = 4.1 \times 10^{-6} \)).

**Conditional GWAS #1 (Table 1, conditional analysis).** We next performed a conditional GWAS meta-analysis, where each study included, as additional covariates to the original analysis plan, the ten genome-wide significant autosomal SNPs (the eight ‘Main’ signals from Table 1 and the two unique SHBG locus signals described above in addition to the lead SNP rs12150660: rs6258 and rs1625895). Three additional signals (independence based on HapMap \( r^2 < 0.05 \)) at the SHBG locus reached genome-wide significance (rs1641537 \( p = 7.8 \times 10^{-12} \), rs6259 \( p = 1.5 \times 10^{-12} \) and rs10432029 \( p = 3 \times 10^{-7} \)), giving a total of six independent signals in this genome region. In addition, two novel signals reached genome-wide significance in the conditional analysis, at 7q21.3 (rs3779195 \( p = 1.1 \times 10^{-8} \)) and 2p16.3 (rs10454142 \( p = 3 \times 10^{-8} \)). After replication, only rs3779195 at the BAAP2L1 locus retained genome-wide significance.

**Conditional analysis #2 (Table 2, full model).** Given the six signals observed at the SHBG locus (three through conditional analysis #1 rs12150660, rs6258, rs1625895, three through LD estimates from conditional GWAS #1: rs1641537, rs6259, rs10432029), we sought to confirm which of these six were truly independent by a second round of conditional analysis. All discovery and replication cohorts fitted a single regression model of the six SNPs (SNPs # 1–6, Table 2) against SHBG concentrations, using the same parameters and covariates as conditional analysis #1. Four of the six SNPs (#1–4: rs12150660, rs6258, rs1641537, and rs1625895) retained genome-wide significance when conditioned against each other, with two showing nominal evidence of association (SNP #5 rs6259, \( p = 0.0001 \); SNP #6 rs10432029, \( p = 0.01 \)).

**Conditional GWAS #2 (Table 2, conditional model).** Finally, we performed a second conditional GWAS analysis, adjusting for the six SHBG locus SNPs which had evidence of association from conditional analysis #2. All the discovery cohorts were used in this analysis, in addition to three replication cohorts (total sample size 24,354). This analysis revealed evidence for a further three independent signals at the SHBG locus (based on HapMap \( r^2 < 0.01 \)), SNP #7 rs9901675 \( p = 1.5 \times 10^{-7} \), SNP #8 rs8077824 \( p = 4.6 \times 10^{-5} \), and SNP #9 rs9393218 \( p = 9.9 \times 10^{-6} \).

**Sensitivity Analysis—Allelic Heterogeneity at the SHBG Locus**

We performed a sensitivity analysis using samples from the 1966 Northern Finland Birth Cohort (NBFC1966) study to further investigate allelic heterogeneity at the SHBG locus (Text S1). The conditional meta-analysis showed evidence for up to nine signals at the SHBG locus, but it is possible that these signals could be explaining a much smaller number of causal variants in the region. Since 1000 Genomes imputation allows us to assess the genetic variation associated with a phenotype across a much denser set of markers, it increases our power to detect allelic heterogeneity within a region. Therefore, 1000 Genomes imputation was carried out on all the samples in the NBFC1966 study and forward selection was used to identify the set of SNPs that best explain the variation in the SHBG phenotype. 1000 Genomes imputation was carried out using IMPUTE2. The mean genotype probabilities for each SNP were calculated and used in the model selection step. Only SNPs 250 kb upstream and 250 kb downstream from the SHBG locus (7283453–7786700 bp) were used in the analysis. All SNPs with MAF <0.1% or an imputation quality score less than 0.4 were excluded from the analysis. In total, 1978 SHBG region SNPs measured or imputed in 4467 samples from the NFBC1966 study were used in the sensitivity analysis. Forward selection was implemented in R (version 2.13.0) using the stepAIC package to estimate the Akaike Information Criterion (AIC), an inclusion parameter. Given the high degree of correlation between the SNPs in this region, we increased the penalty \( k \) on the number of terms included in the model to 12 (where it is usually two), to minimize possible over fitting. The final model included seven SNPs, adjusted for sex and BMI.

**Pathway Analysis**

We examined potential interactions among the proteins encoded by the SHBG locus and the proteins encoded by the 11 genes (ZBT10, TEDG1, ZNF632, PRMT6, JMJD1C, GCRK, BAAP2L1, LHCGR, SLC10A1, UGT2B15, NR2F2) closest to the 11 identified SNPs using pathway analysis with Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) Pathways Analysis (www.string-db.org). The interactions explored by STRING include direct (physical) and indirect (functional) associations. We then expanded the analysis to examine protein interactions among the SHBG gene and the proteins encoded by 67 genes within 500 kb of the 11 identified SNPs.

**Targeted Candidate Gene Analysis**

We conducted targeted analysis of two strong candidate genes, hepatocyte nuclear factor-4a (HNF4a) and peroxisome-proliferating receptor \( \gamma \) (PPAR\( \gamma \)). Statistical significance thresholds were set correcting for the number of SNPs tested in each gene region (±100 kb).

**Supporting Information**

**Table S1** Characteristics of 21,791 individuals from 10 discovery cohorts included in the meta-analysis.

**Table S2** Characteristics of 8,175 individuals from the six cohorts included in the validation analysis (WHI, CARDIA, Prospect-EPIC, MrOs, NHS, YFS) and the independent cohort used to estimate the proportion of genetic variance explained by the identified SNPs (IntChianti).

**Table S3** Hapmap (release 22) linkage disequilibrium estimates for the nine SHBG gene locus single nucleotide polymorphisms.

**Text S1** Supplementary Methods with Specific Cohort Information.

**Acknowledgments**

We are grateful to all study participants and staff in our participating studies. Full study acknowledgements are available in Text S1.

**Author Contributions**

Conceived and designed the experiments: FH de Jong, O Raitakari, A Teumer, C Olsson, JM Murabito, JRB Perry. Analyzed the data: JRB Perry, AD Coviello, R Haring, M Wellons, D Vaidya, T Lehtimäki, S Keildson, KL Lunetta, C He, M-R Jarvelin. Wrote the paper: AD Perry, AR Coviello, RH Haring, MW Wellons, DV Vaidya, TL Lehtimäki, SK Keildson, KL Lunetta, CH He, TM Frayling, AM Murray, SR Franks, MR Jarvelin, FH de
Jong, O Raitakari, A Teumer, C Ohlsson, JM Murabio, JRB Perry, Individual cohort phenotyping/genotyping: KL Lunetta, C He, M Fornage, V Lagou, M Mangino, NC Ouland-Moret, B Chen, J Eriksson, M Garcia, YM Liu, A Koster, K Lohman, L-P Lytyikäinen, A-K Petersen, J Prescott, L Stolk, I Vanderpuy, AR Wood, WV Zhuang, A Ruokonen, A-L Hartikainen, A Pouta, S Bandinelli, AD Covello, R Bíftar, G Brabant, DG Cox, Y Chen, S Cummings, I Ferrucci, MJ Gunter, SE Hankinson, H A-L Hartikainen, A Pouta, S Bandinelli, AD Coviello, R Biffar, G Brabant, 20. Chen ZJ, Zhao H, He L, Shi Y, Qin Y, et al. (2011) Genome-wide association 19. Franks S, Gharani N, McCarthy M (2001) Candidate genes in polycystic ovary syndrome. Clin Endocrinol 55: 95–98. 18. Harrison MJ, Tang YH, Dowhan DH (2010) Protein arginine methyltransferase 2 regulates multiple aspects of gene expression. Nucleic Acids Res 38: 2201–2216. 17. Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, et al. (2010) MicroRNA-27a indirectly regulates Estrogen Receptor (alpha) Expression and Hormone Responsiveness in MCF-7 Breast Cancer Cells. Endocrinology 151: 2462–2473. 16. Harrison MJ, Tang YH, Dowhan DH (2010) Protein arginine methyltransferase 6 regulates multiple aspects of gene expression. Nucleic Acids Res 38: 2201–2216. 15. Martin LJ, Tremblay JJ (2010) Nuclear receptors in Leydig cell gene expression and function. Biol Reprod 83: 8–14. 14. Hu Z, Xia Y, Guo X, Dai J, Li H, et al. (2011) A genome-wide association study in Chinese men identifies three risk loci for non-obstructiveazoospermia. Nat Genet 43: 183–186. 13. Li X, Mertens-Talcott SU, Zhang S, Kim K, Ball J, et al. (2010) MicroRNA-27a Indirectly Regulates Estrogen Receptor (alpha) Expression and Hormone Responsiveness in MCF-7 Breast Cancer Cells. Endocrinology 151: 2462–2473. 12. Han SY, Zhou L, Upadhyaya A, Lee SH, Parker KL, et al. (2001) TFIIAalpha/β/γ/δ, C1orf34, 2p16.3, 2p21 and 9q33.3. Nat Genet 43: 55–59. 11. Chasman DI, Pare G, Mora S, Hopewell JC, Peloso G, et al. (2009) Forty-three genetic determinants of serum testosterone concentrations in men. PLoS Genet 5: e1002313. doi:10.1371/journal.pgen.1002313 10. Ohlsson C, Wallaschofski H, Lunetta KL, Stolk L, Perry JR, et al. (2011) Genetic and environmental factors associated with triglycerides in young men: the HEI-2010 study. J Intern Med 269: 425–433. 9. Melzer D, Perry JR, Hernandez D, Corsi AM, Stevens K, et al. (2008) A genome-wide association study of endocytosis in cellular uptake of sex steroids. Cell 122: 751–762. 8. Waskell J, Michal M, Solomon N, Wardle PG (2011) The value of sex hormone-binding globulin (SHBG) in predicting treatment response in polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab 96: 495–499. 7. Perry JR, Weedon MN, Langenberg C, Jackson AU, Lyssenko V, et al. (2010) A genome-wide association study of plasma lipoprotein size, concentration, and cholesterol and triglyceride levels. J Clin Endocrinol Metab 95: 5976–5980. 6. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, et al. (2009) Sex hormone-binding globulin promoter activity is influenced by a (TAAAA)n repeat element within the SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute Japanese women. J Mol Genet Endocrinol 43: 55–59. 5. Xita N, Tatsoulis A, Chatziyiakoula A, Georgiou I (2003) Association of the (TAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 88: 5976–5980. 4. Thompson DJ, Healey CS, Baynes C, Kalmyrzaev B, Ahmed S, et al. (2000) Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17: 3490–3498. 3. Thompson DJ, Healey CS, Baynes C, Kalmyrzaev B, Ahmed S, et al. (2000) Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17: 3490–3498. 2. Hammond GL (2011) Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod 85: 431–441. 1. Hammond GL (2011) Diverse roles for sex hormone-binding globulin in reproduction. Biol Reprod 85: 431–441.
44. Buch S, Schafmayer C, Völkle H, Seeger M, Miquel JF, et al. (2010) Loci from a genome-wide analysis of biallelic variants are associated with gallstone risk and composition. Gastroenterology 139: 1942–1951 e1942.
45. Miyahara A, Okamura-Oho Y, Miyashita T, Hoshika A, Yamada M (2003) Genomic structure and alternative splicing of the insulin receptor tyrosine kinase substrate of 33-kDa protein. J Hum Genet 48: 410–414.
46. Galligan CL, Baig E, Byrker V, Keystone EC, Fuh EN (2007) Distinctive gene expression signatures in rheumatoid arthritis synovial fibroblast cells: correlates with disease activity. Genes Immun 8: 480–491.
47. Millard TH, Dawson J, Mackesy LM (2007) Characterisation of IRTKS, a novel IRS5p3/MIM family actin regulator with distinct filament bundling properties. J Cell Sci 120: 1663–1672.
48. Dupuis J, Langenberg C, Prokopenko I, Saxena R, Soranzo N, et al. (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42: 103–116.
49. Wang L, Maruotto N, Hayashi H, Mitani Y, Urakha H, et al. (1997) Hyperinsulinaemia but no diabetes in transgenic mice homozygously expressing the tyrosine kinase-deficient human insulin receptor. Biochem Biophys Res Commun 240: 446–451.
50. Hostamniglid GS, Budavari A, Murray D, Spiegelman BM (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94: 1543–1549.
51. Kusari J, Takata Y, Hatae E, Freidenberg G, Koltermann O, et al. (1991) Insulin resistance and diabetes due to different mutations in the tyrosine kinase domain of both insulin receptor gene alleles. J Biol Chem 266: 5260–5267.
52. Block NE, Komori K, Robinson KA, Dutton SL, Lam CF, et al. (1991) Diabetes-associated impairment of hepatic insulin receptor tyrosine kinase activity: a study of mechanisms. Endocrinology 129: 312–322.
53. Odawara M, Kadowaki T, Yamamoto R, Shiibashi Y, Toke K, et al. (1989) Human diabetes associated with a mutation in the tyrosine kinase domain of the insulin receptor. Science 245: 66–68.
54. Arner P, Polare T, Lihll E, Livingston JN (1987) Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 437–440.
55. Selva DM, Hammond GL (2009) Peroxisome-proliferator receptor gamma represses hepatic sex hormone-binding globulin expression. Endocrinology 150: 2183–2189.
56. Ashburger D, Hirschhorn JN, Klaunemann M, Lindgren CM, Vohl MC, et al. (2008) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26: 76–80.
57. Hakonarson H, Grant SF (2011) GWAS and its impact on elucidating the etiology of diabetes. Diabetes Metab Res Rev.
58. Selva DM, Hovegen KN, Innes SM, Hammond GL (2007) Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 117: 3979–3987.
59. Shih DQ, Bussen M, Schayek E, Ananthanarayanan M, Shneider BL, et al. (2000) Hepatocyte nuclear factor-1alpha is an essential regulator of bile acid and plasma cholesterol metabolism. Nat Genet 27: 375–382.
60. Yin L, Ma H, Ge X, Edwards PA, Zhang Y (2011) Hepatic hepatocyte nuclear factor-1alpha is essential for maintaining triglyceride and cholesterol homeostasis. Arterioscler Thromb Vasc Biol 31: 528–536.
61. Wilson W, 3rd, Pardo-Manuel de Villena F, Lyn-Cook BD, Chatterjee PK, Bell TA, et al. (2004) Characterization of a common deletion polymorphism of the UGT2B17 gene linked to UGT2B15. Genomics 84: 707–714.
62. Turgon D, Carrier JS, Levesque E, Hun DW, Belanger A (2001) Relative enzymatic activity, protein stability, and tissue distribution of human steroid metabolizing UGT2B subfamily members. Endocrinology 142: 778–787.
63. Menard V, Eap O, Harvey M, Guillermette C, Levesque E (2009) Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B2 and their associations with a UGT2B15 functional polymorphism. Hum Mutat 30: 1310–1319.
64. Levesque E, Beaulieu M, Green MD, Tephy TR, Belanger A, et al. (1997) Isolation and characterization of UGT2B15(Y51): a UDP-galactosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7: 317–325.
65. Swanson C, Mellstrom D, Lorentzon M, Vandenput L, Jakobsson J, et al. (2007) The uridine diphosphate glucuronosyltransferase 2B13-D53Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and ltd fat mass. J Clin Endocrinol Metab 92: 4878–4882.
66. Chouinard S, Barbier O, Belanger A (2007) UDP-galactosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells. J Biol Chem 282: 33466–33474.
67. Chouinard S, Pelletier G, Belanger A, Barbier O (2004) Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium. Endo Res 30: 717–725.
68. Pathi JS, Jatooru I, Chadrakahan G, Sreevalsan S, Anand S, et al. (2011) GT094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol Cancer Res 9: 195–202.
69. Kumar R, Manning J, Spenlove HE, Kreemidisioti G, Mcquirdy R, et al. (2006) ZNF652, a novel zinc finger protein, interacts with the putative breast tumor suppressor CBFA2T3 to repress transcription. Mol Cancer Res 4: 655–664.
70. Kumar R, Seth L, Schulz RB, Tay BS, Nielsen PM, et al. (2011) Genome-wide mapping of ZNF652 promoter binding sites in breast cancer cells. J Cell Biochem. 71. Kumar R, Cheney KM, Nielsen PM, Schulz RB, Callen DF (2010) CBFA2T3-ZNF652, like CBFA2T3-ZNF652, functions as a transcriptional corepressor complex. FEBS Lett 584: 859–864.
72. Callen DF, Ricciardelli C, Butler M, Stapleton A, Stahl J, et al. (2010) Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncol Rep 23: 1045–1052.
73. Baldassarre G, Romano A, Armenante F, Kambahdi M, Fasotti L, et al. (1997) Expression of teratocarcinoma-derived growth factor-1 (TDFG-1) in testis germ cell tumors and its effects on growth and differentiation of embryonal carcinoma cell line NTERA2/D1. Oncogene 15: 927–936.
74. Burger HG, Dudley EC, Cui J, Demestren L, Hopper JL (2000) A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrinol Metab 85: 2832–2838.
75. Schijf CP, van der Mooren MJ, Duesborg WH, Thomas CM, Rolland R (1993) Differences in serum lipids, lipoproteins, sex hormone binding globulin and testosterone between the follicular and the luteal phase of the menstrual cycle. Acta Endocrinol (Copenh) 129: 130–133.
76. Link E, Parish S, Armitage J, Bowman L, Heath S, et al. (2008) SLC01A1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359: 789–799.
77. Chambers JC, Zhang W, Schmi J, Li X, Wiss MN, et al. (2011) Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 43: 1131–1138.
78. Lee DK, Kurihara I, Jeong JW, Lydon JP, DeMayo FJ, et al. (2010) Suppression of ERalpha activity by COUP-TFI is essential for successful implantation and decidualization. Mol Endocrinol 24: 930–940.